HealthCare Institute of New Jersey (HINJ) President and CEO Chrissy Buteas has expressed support for life sciences companies following the Trump administration’s recent recommendations that women limit Tylenol use during pregnancy unless medically necessary.
Buteas stated, “From rigorous R&D and clinical trials to comprehensive approval and regulatory processes, life sciences companies have long partnered with safety and efficacy agencies in the U.S. and globally to ensure that patient safety remains the cornerstone of advancing human health.” She added, “They remain committed to upholding the highest standards of scientific integrity and medical safety as they pursue their mission: to improve and save lives worldwide.”
HINJ represents research-based biopharmaceutical and medical technology companies in New Jersey, including both large multinational firms and smaller businesses.
The Food and Drug Administration, under President Trump, announced it would begin changing the safety label on acetaminophen products. The agency also sent a letter to physicians emphasizing that decisions about Tylenol use should be made by parents.
Some members of the scientific community criticized the administration’s suggestion of a link between acetaminophen products and autism.
Kenvue, a company based in New Jersey that manufactures Tylenol, issued a statement disagreeing with claims that acetaminophen causes autism. The company said it is concerned about potential health risks and confusion for expecting mothers and parents. Kenvue stated, “Acetaminophen is the safest pain reliever option for pregnant women as needed throughout their entire pregnancy. Without it, women face dangerous choices: suffer through conditions like fever that are potentially harmful to both mom and baby or use riskier alternatives. High fevers and pain are widely recognized as potential risks to a pregnancy if left untreated.”
